Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × Cyclosporine × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 90 Leukemia 87 Precursor Cell Lymphoblastic Leukemia-Lymphoma 85 Myelodysplastic Syndromes 73 Leukemia, Lymphocytic, Chronic, B-Cell 72 Lymphoma, Non-Hodgkin 67 Multiple Myeloma 58 Lymphoma, Mantle-Cell 58 Hodgkin Disease 58 Lymphoma, Large B-Cell, Diffuse 55 Lymphoma 55 Lymphoma, Follicular 53 Leukemia, Myeloid, Chronic-Phase 51 Lymphoma, B-Cell, Marginal Zone 48 Burkitt Lymphoma 48 Lymphoma, Large-Cell, Immunoblastic 44 Leukemia, Myeloid, Accelerated Phase 44 Leukemia, Myelomonocytic, Chronic 40 Congenital Abnormalities 40 Myeloproliferative Disorders 38 Anemia, Refractory, with Excess of Blasts 36 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34 Graft vs Host Disease 33 Blast Crisis 31 Recurrence 29 Dendritic Cell Sarcoma, Interdigitating 29 Primary Myelofibrosis 25 Lymphoma, T-Cell, Cutaneous 24 Neoplasms, Plasma Cell 23 Sezary Syndrome 22

Interventions

efgartigimod alfa 10 rozanolixizumab 9 Prednisone 8 zilucoplan 7 Pyridostigmine Bromide 7 Cyclophosphamide 7 telitacicept 6 Tacrolimus 6 Rituximab 6 ravulizumab 5 fludarabine 5 eculizumab 5 Mycophenolic Acid 4 Hizentra 4 Steroids 3 Immunoglobulins, Intravenous 3 HBM9161 3 Data Collection 3 Azathioprine 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Thymectomy 2 Prednisolone 2 Methylprednisolone 2 Methotrexate 2 Blood Specimen Collection 2 tofacitinib 1 tocilizumab 1 satralizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04101578 2021-08-23

Clinical Prognosis and Progression of Myasthenia Gravis Patients

Da, Yuwei, M.D.

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡